PacBio reports fourth quarter revenue growth of 14% year-over-year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
January 12, 2026 9:05 AM ESTMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively.
We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications, said Christian Henry, President and CEO of PacBio. In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Looking ahead, we... More
